Ann: Half Year Report and Financial Statements, page-12

Just re-read this half yearly, the thing that jumped out at me was we ended the 6months with $1.1m cash, raised $3m from SH's in the CR and $4.5m from instos = $8.6m cash position = very healthy. With a current MCAP of $19m, that places a value of $10.4m on DMX-200 AND our HIIT platform combined. I can't help but laugh at how asleep the market is here!!

It reminds me of one of my other holdings, TAW, I bought at 15c and everybody complained for ages about how under the radar it was (funny enough people still saying the same now at 45c and I'm just enjoying the ride) The fact is these companies have good management teams that focus on the business, not the share market, knowing that the stock price will take care of itself in time.

Other research I've done has been on other BioMed companies that made it to Phase 2b trials and failed. Lookup Innate Imunotherapeutics as an example.. These companies had Managing Directors that could generate interest in the SP (what our friend Stormer so wishes we had here) Their SP rose and rose heading in to the 2B trials because their board has that charisma (that Stormer wishes we had here) The problem was, despite all that charisma, the Science didn't back it up and the SP tank 90% in a day. I would say Dimerix are the complete antithesis in that regard. Whilst, and this definitely is not my opinion btw, we lack the charisma and leaders to excite people and get investors on board, we have highly skilled highly qualified members, going about their business, not worrying about the interest or lack of interest in our share price, perfecting our Science, doing everything they can so that Phase 2B comes out with blockbuster results that changes people's health and lives, and giving us and themselves a massive pay day! The $8.6m will see this to fruition.